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doi:10.1Objective: This study was undertaken to evaluate safety and biocompatibility of a novel biodegradable poly-
dioxanone stent in a rabbit tracheal model. Metallic and silicone stents represent standard therapeutic ap-
proaches for hollow organ stenosis, although complications have been reported repeatedly. Biodegradable
stents could reduce the risks associated with this procedure while still achieving the purpose of maintaining
lumen patency.
Methods: A commercially available polydioxanone suture strand with a long safety record was used to manu-
facture the self-expanding stents. The polydioxanone stents were then implanted bronchoscopically and under
fluoroscopic guidance into the tracheas of white rabbits (N¼ 25). Periodic clinical examination was performed.
Histopathologic examination concluded the study for the 5 experimental groups at 3, 4, 5, 10, and 15 weeks after
implantation.
Results: There were no unexpected deaths and no stent displacements during the study. The animals remained in
good condition, without stent debris expectoration. Macroscopic examination revealed that the tracheal lumen
stayed open. Histologic examination showed that tracheal damage score was highest 5 weeks after stenting, in-
cluding in-stent necrosis of the epithelium. Stent degradation was complete with no remnants after 10 weeks,
leaving the trachea completely healed at 15 weeks after implantation.
Conclusions: This animal airway model has demonstrated acceptable safety and biocompatibility of this novel
biodegradable polydioxanone stent. We suggest that polydioxanone stenting be used for further clinical studies
for cases in which complete stent degradation after temporary airway treatment is desirable. (J Thorac Cardio-
vasc Surg 2012;143:437-44)E
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SStenting is an important therapeutic modality for the main-
tenance of lumen patency in different tubular organs.
For airways, there are 4 categories of stent currently avail-
able: silicone stents, balloon-dilated metal stents, self-
expanding metal stents, and hybrid silicone and metal stents
(covered self-expanding metal stents).1 Silicone stents tend
to migrate and disturb airway mucociliary clearance. Metal-
lic stents cannot be removed once embedded in thewall, and
they pose the risk of a secondary stenosis as a result of
hyperplastic granulation.2 In children with severe tracheo-
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The Journal of Thoracic and Caan unacceptable risk because of the previously mentioned
erosion by these metal and plastic frameworks.3
To avoid the mechanical complications associated with
nonabsorbable stents, many groups have focused on the de-
velopment of absorbable stents. Currently, there are a few
bioabsorbable and biodegradable materials available for
construction of such stents, such as poly-L-lactic acid, poly-
glycolic acid, polycaprolactone, poly(lactic-co-glycolic
acid), and polydioxanone.4 Polydioxanone (poly-p-dioxa-
none) is a monofilament, absorbable material widely used
as a suture in soft tissue surgery.5 It is a biodegradable,
semicrystalline polymer belonging to the polyester group.
Its monofilament has a degree of ‘‘shape memory’’ and
tends to coil. It degrades by random hydrolysis of its molec-
ular ester bonds. Degradation accelerates at low pH. All
degradation products and their intermediates are harmless.
The degradation process occurs in 2 stages. The first in-
volves amorphous regions of the matrix, the second the
crystalline areas of the polymer. Because mechanical and
physical properties depend much on the presence of the
crystalline areas, the mechanical effect of degradation is
not linear.6
Biodegradable stents have already been developed for
esophageal, intestinal, urethral, biliary duct, and vascular
stenoses.7-10 Various biodegradable materials have been
used experimentally for stenting of tracheobronchial
stenosis since 1998.11-14 The first results of polydioxanonerdiovascular Surgery c Volume 143, Number 2 437
Abbreviation and Acronym
TDS ¼ tracheal damage score
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transplant have recently been published,15 but the degrada-
tion time of polydioxanone stents in the trachea or bronchi
remains to be defined. These stents have, however, been
shown to be well tolerated by tracheal mucosa, to maintain
biomechanical strength for as long as 6 weeks, and to dis-
solve completely by 15 weeks.16 Ongoing animal studies
should further clarify the efficacy and safety of polydioxa-
none airway stenting. The stent material in this anatomic lo-
calization is hypothetically partly absorbed and partly
expectorated. The main goals of our experiment were to
identify a tissue reaction to the polydioxanone stent in
the rabbit trachea and to estimate the degradation time of
such stents.
MATERIALS AND METHODS
Stents and Implantation Technique
The braided stents had a diameter of 6 mm and a length of 30 mm
(Figure 1, A) and were manufactured (ELLA-CS sro, Hradec Kralove,
Czech Republic) from commercially available polydioxanone monofila-
ment (Samyang Co, Seoul, Korea) of 0.340 to 0.399 mm (EP3) in diameter.
Currently, only esophageal biodegradable stents of a larger caliber are com-
mercially available from the same manufacturer. A 6-mm diameter was
chosen for the stent because it was approximately 15% larger than the nor-
mal physiologic diameter of the rabbit trachea, which measures 4.71 mm in
its ventral–dorsal diameter and 5.92 mm in its lateral diameter with an av-
erage length of 55 to 58 mm in animals with a body weight of 3.00 to
3.50 kg.17
The stent was fitted with radiopaque markers at each end. The sterilized
stent was delivered in an airtight container, which was opened immediately
before implantation to minimize stent degradation by humidity. The stent
was loaded manually into the delivery system (12F, 4 mm in outer diameter
and 40 cm in active length), which was composed of a hollow plastic guid-
ing tubewith an olive tip designed to accept a 0.89-mm (0.035-inch) guide-
wire and an overtube (Figure 1, B).
As it is loaded into the delivery system, the stent elongates. To establish
mechanical deformation resistance during stent elongation, a local com-
pression test was carried out by the manufacturer. The eccentric localized
(point) load method18 was chosen for different constrictions and elonga-
tions of the 12 3 40-mm stent. Stress as a measure of force per unit area
was expressed in grams per square centimeter. The stress necessary to col-
lapse the diameter of the stent to 50% of its pretest diameter was
established.
The in vitro degradation of polydioxanone by hydrolysis had been
examined previously in the manufacturer’s laboratories. In these tests, pol-
ydioxanone stents (‘‘dog bone’’ configuration 23 mm 3 18 mm 3
23 mm3 60 mm) were immersed in phosphate-buffered normal saline so-
lution at 37C, and the reduction in radial resistive force was examined se-
rially for 12 weeks.
Animal Study
All animals received humane care in accordance with the ‘‘Principles of
Laboratory Animal Care’’ formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory Animals’’438 The Journal of Thoracic and Cardiovascular Surg(www.nap.edu/catalog/5140.html) prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by the Na-
tional Academy Press, revised in 1996. All experiments were performed
with the permission of and under the supervision of the ethics committee
of the Faculty of Military Health Sciences (Hradec Kralove, Czech
Republic).
Thirty White New Zealand 10-month-old female rabbits with average
weight of 3.2 kg were allotted to 6 groups of 5. Five groups were used
for implantation of the intratracheal stent, and 1 group was an untreated
control group. Animals were placed in the Animal House of the Faculty
of Military Health Sciences of The Czech University of Defence. Rabbits
were fed unrestrictedly, with all-day access to water. Rabbits were kept in
separate cages in isolated room with the temperature 20C and humidity
50% with 12-hour light cycles.
For stent implantation, the rabbits were anesthetized with xylazine
(3 mg/kg intramuscularly) and ketamine (30 mg/kg intramuscularly).
This was followed by anesthesia prolongation with the same agents (50%
of initial doses every 20 minutes) through an intravenous cannula placed
into the aural lateral vein. The animals breathed spontaneously during the
operation, with oxygen supplementation by endoscope during the time of
the stent implantation.All animalswere examined by fluoroscopy and bron-
choscopy before stent implantation. The diameter of the tracheal lumenwas
measured, and the polydioxanone stent was delivered to the middle trachea
with the delivery system under fluoroscopic guidance with the aid of
a guidewire. After placement of the stent, its position and expansion in
the tracheal lumen were examined by bronchoscopy and fluoroscopy
(Figure 1, C and D). Bronchoscopy was also performed every 4 weeks
and immediately before histopathologic examination (Fujinon Video Pro-
cessor, EPX-4400HD, and flexible videobronchoscope Fujinon EB–470P,
diameter 3.8 mm and length 60 mm; Fujinon, Osaka, Japan). The animals
were anesthetized for bronchoscopies with intramuscular injections of me-
detomidine hydrochloride (INN medetomidine, 0.25 mg/kg) and ketamine
(30 mg/kg).
The animals were clinically observed daily, and any respiratory distress
was recorded. We have used the following grading of respiratory distress:
normal, respiration without stridor with normal rate; mild distress, inter-
mittent stridor on exertion only, with normal appetite and intake of water;
moderate distress, intermittent stridor also in rest, mostly inspiratory, in-
creased respiration rate, increased intake of water, and some nasal watery
discharge; and severe distress, continuous inspiratory and expiratory stri-
dor, rich mucopurulent nasal discharge, overall labored respiration, higher
intake of water, and decreased appetite.
Finally, the animals were killed at 3, 4, 5, 10, and 15 weeks after stent
implantation (groups W3, W4, W5, W10, and W15, respectively) with in-
travenous injection of T61 (200 mg embutramide, 50 mg mebozonium io-
dide, and 5 mg tetracaine hydrochloride) at a dose of 0.3 mL/kg. Complete
histopathologic examination followed. Rabbits in the control group were
killed along with animals in the last group (15 weeks after implantation
in the experimental groups). The whole trachea, including the stented
area, was collected and immersed in buffered 10% formalin for histopath-
ologic study.
Histopathologic Analysis
Tracheal samples were fixed in 10% buffered formalin and processed
with the standard histologic paraffin technique with staining by hematoxy-
lin and eosin. Slides were observed with an optical microscope (Olympus
BX 51; Olympus, Aomori, Japan) with a digital output (Olympus DP 71
camera).
Semiquantitative Analysis of Tracheal Tissue
Reaction
The type and degree of tissue reaction severity, including the amount of
inflammatory cells in the tissue samples, were assessed in 6 randomly
selected microscopic view fields from each animal at high powerery c February 2012
FIGURE 1. A, Graphic evaluation of statistically significant differences between control group and all experimental groups (Mann-Whitney U test, all
P<.009) in tracheal damage score. B, Graphic evaluation of statistically significant differences in tracheal damage score between experimental groups.
(Mann-Whitney U test, all P< .009). C, Graphic evaluation of statistically significant differences in respiratory distress in all animals week by week
(Mann-Whitney U test, weeks 2–8, P<.009).
TABLE 1. Grading system for tracheal tissue lesions: Tracheal
damage score
Grade Definition
0 Normal histologic structure
1 Mild damage: Mild epithelial hyperplasia; mild
lymphoplasmacytic infiltration of lamina propria;
fibrocartilaginous layer of normal morphology either
adventitia; mild fibroplasia in lamina propria
2 Moderate damage: Epithelium moderately hyperplastic with
pronounced hyperplasia of goblet cells and moderate
infiltration with heterophils; moderate lymphoplasmacytic
infiltration of lamina propria; fibrocartilaginous layer of
normal morphology either adventitia; moderate fibroplasia
in lamina propria
3 Severe and focal damage: Segmental necrosis of the
epithelium and lamina propria; necrosis surrounded by
moderate fibroplasia with scattered heterophils,
lymphocytes, and plasma cells; fibrocartilaginous layer of
normal morphology either adventitia
4 Severe diffuse damage: Severe necrosis of tracheal mucosa
affecting also fibrocartilaginous layer; severe accumulation
of inflammatory cells and massive hemorrhage
5 Transmural necrosis: Diffuse severe tissue necrosis of all the
tracheal layers
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damage score (TDS) scale of 0 to 5, according to the degree of cellular de-
generation, necrosis, inflammation, hemorrhage, and edema of tissue, as
well as the number of foci involved (Table 1). This grading was based on
a previously published 4-grade scoring system12 with a grade of 5 (trans-
mural necrosis) added.
Statistical Analysis
Statistical evaluation was performed with commercial statistical soft-
ware (Stat for Windows, R.4.5; Stat Soft, Inc, Tulsa, Okla) with the
Mann-Whitney U test or Kruskal-Wallis analysis of variance. Figure 1
shows results as mean  SD.
RESULTS
Stents and Implantation
The stent in its nominal relaxed diameter of 6 mm and
length of 30 mm exerts a radial expansion force of zero. Ac-
cording to the manufacturer’s own measurements, the
12 3 40-mm stent lengthens by approximately 20% as its
diameter constricts by 1 mm, and the expansion force jumps
to 106.3 g/cm2. By maximal compression to half its original
diameter, the stent achieves 150% of its original length, and
the expansion force grows to 364.2 g/cm2. During the first
5 weeks of in vitro degradation, the radial resistive forces
persisted at around the initial values. At week 7, the radial
force was about 2 thirds of the initial force, and in week 9
about half.
All stents were successfully delivered and deployed
into the trachea with no technical problems. Loading
duration of the stent into the delivery device improvedThe Journal of Thoracic and Cawith practice from 5 minutes to 1 minute, and the deliv-
ery of the stent into the tracheal lumen was managed
quite easily. The original apnea duration of 200 seconds
was reduced after the first 5 implantations to less thanrdiovascular Surgery c Volume 143, Number 2 439
FIGURE 2. A, Biodegradable polydioxanone stent with 2 golden markers. B, Loaded stent and delivery system. C, Stent on bronchoscopy immediately
after implantation. D, Fluoroscopic control of stent positioning.
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gration nor stent fractures were observed on the control
radiographs or bronchoscopies carried out after the
procedure.
Animal Study
Mild clinical signs of respiratory distress were seen in the
first 2 weeks after implantation. The difference in clinical
impairment from week 2 to week 8 was statistically signif-
icant (Figure 2, C). The rabbits had shown expiratory and
inspiratory stridor in this time, as well as mild to moderate
mucopurulent nasal discharge. Higher intake of water and
decreased appetite were also observed during this period.
From week 5 onward, signs of respiratory distress progres-
sively decreased, and during the final 2 weeks (from the
14th through the 15th week), only mild stridor was
observed.440 The Journal of Thoracic and Cardiovascular SurgHistopathologic Analysis
Group W3 (killed third week after implantation; TDS
range, 2–3). Macroscopically, the polydioxanone stent
was seen to be fully intact at 3 weeks, without signs of in-
flammation (Figure 3, A). Microscopically, necrosis of the
epithelium and lamina propria at the point of contact be-
tween the polydioxanone strand and the mucosa was seen.
Necrosis was surrounded by moderate fibroplasia and scat-
tered heterophils and lymphocytes (Figure 4,A). Epithelium
between polydioxanone strands was moderately hyperplas-
tic, with pronounced hyperplasia of goblet cells and mildly
heterophil infiltration. Adjacent lamina propria was moder-
ately infiltrated with heterophils and fibroblasts (Figure 4,
D). The underlying fibrocartilaginous layer and adventitia
were of normal morphology. The part of the trachea adja-
cent to the stent showed only mild lymphoplasmacytic infil-
tration of the lamina propria. Regional (cranial thoracic)ery c February 2012
FIGURE 3. A, Rabbit trachea with stent in place 3 weeks after implantation. B, Trachea with severe inflammation and hemorrhages 4 weeks after implan-
tation, stent removed. C, Discolored polydioxanone stent together with exudation and hyperplasia of mucosa 5 weeks after implantation. D, No stent is
present in the trachea at 10 weeks after implantation; however, persistent inflammation and hyperplasia are present. E, Tracheal mucosa is slightly hyperemic
with no signs of hyperplasia at 15 weeks after implantation. There is no more stent in the trachea, and there is only minimal scar tissue (asterisk).
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perplasia of the cortical lymphatic follicles (reactive
hyperplasia).
Group W4 (killed fourth week after implantation; TDS
range, 2–4). The stent was still intact at 4 weeks, and the
mucosa was markedly hyperplastic and inflamed
(Figure 3, B). Histologically, we observed severe purulent
inflammatory infiltrate adherent to the mucosa, with large
areas of desquamation of the epithelium (Figure 4, B). Fi-
broplasia in the lamina propria was moderate to severe,
with mild to moderate angiogenesis. Tracheal tissue adja-
cent to the stent showed mild infiltration, with a moderate
amount of lymphocytes and plasma cells in the lamina
propria.
Group W5 (killed fifth week after implantation; TDS
range, 3–4). At 5 weeks, discolored polydioxanone
stent (Figure 3, C) was present macroscopically, as
well as exudate and hyperplasia of mucosa. Microscop-
ically, we observed marked fibroplasia around the stent
strands and heterophilic infiltration of the epithelium
and lamina propria, with masses of bacteria. In 1The Journal of Thoracic and Caanimal, tracheal cartilage necrosis and replacement by
fibroblast proliferation was observed. Hyperplastic fi-
brous tissue was moderately infiltrated with heterophils
(Figure 4, E).
Group W10 (killed tenth week after implantation; TDS
range, 2–3). At 10 weeks after implantation, we did not
find any stent material in the trachea; however, inflamma-
tion and hyperplasia were observed (Figure 3, D). The ep-
ithelium was hyperplastic, with mild to moderate
infiltration of heterophils. There was marked goblet cell
hyperplasia. Hyperplastic fibrous tissue of the lamina
propria was moderately infiltrated with heterophils and
markedly infiltrated with plasma cells and lymphocytes,
especially perivascularly (Figure 4, C). We did not see
any cartilage damage.
Group W15 (killed fifteenth week after implantation;
TDS range, 1–2). No stent material was present in any of
the animals at 15 weeks after implantation. The mucosa
was slightly hyperemic, but with no signs of hyperplasia.
We noted only minimal scar tissue at the site of previous
stent implantation (Figure 3, E, asterisk).rdiovascular Surgery c Volume 143, Number 2 441
FIGURE 4. A, At 3 weeks after implantation, segmental necrosis of the tracheal mucosa at the previous site of the stent fiber, which has been removed
(Hematoxylin–eosin staining; original magnification,3100). B, At 4 weeks after implantation, rich heterophilic infiltrate between stent strands (asterisks),
desquamation of the epithelium, and congestion of mucosal blood vessels (original magnification, 340). C, At 10 weeks after implantation, hyperplastic
epitheliumwith mild to moderate infiltration of heterophils, hyperplasia of goblet cells, and hyperplastic fibrous tissue of lamina propria markedly infiltrated
with plasma cells and lymphocytes, especially perivascularly (original magnification,3100). D, At 3 weeks after implantation, moderate epithelial hyper-
plasia and mild infiltration of the epitheliumwith heterophils. There is also moderate fibroplasia in lamina propria and moderate infiltration with heterophils
(original magnification3400). E, At 5 weeks after implantation, necrosis of tracheal cartilage with degenerated heterophils (original magnification,3100).
F, At 15 weeks after implantation, marked goblet cell hyperplasia in the tracheal epithelium in the place of previous stent implantation with mild to moderate
lymphoplasmacytic infiltration of the epithelium and lamina propria (original magnification, 3400).
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cytes and showed marked goblet cell hyperplasia
(Figure 4, F). In the locations of macroscopically obvious
scar tissue, we observed hyperplastic fibrous tissue and
mild lymphoplasmacytic infiltration. Mucosa adjacent
to the previously implanted stent was of normal
morphology.
Semiquantitative Analysis of Tracheal Tissue
Reaction and Statistical Analysis
The TDS was highest in group W5 (Figure 2, A), with
a mean damage grade of 3.53  0.51. There were also sig-
nificant differences between the control group and all the
experimental groups (Mann-Whitney U test, all P<.009),
as shown in Figure 2 (B).442 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Various stenting options are available in the airway. Re-
cently, Liu and colleagues19 summarized the evolution of
biodegradable airway stenting and added their experience
with the polycaprolactone airway stent in rabbits. In some
cases, a quick absorption of the stent is desirable. Polydiox-
anone dissolves relatively quickly, and thus many complica-
tions do not have time to evolve. Bronchial stenosis in the
anastomosis after lung transplant and benign tracheal stric-
ture seems to be good indication for this type of stent, as
well as tracheobronchial collapse as a result of malacia or
external compression in children. The type of airway steno-
sis (localized, neoplastic, long-segment, or pulsatile) and
patient age influence the result of biodegradable stenting.
In the growing trachea, the remodeling toward airwayery c February 2012
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nosis. The durability of clinical results of biodegradable
stenting in localized benign bronchial strictures was re-
cently proved. The airway needed multiple stenting, but it
then remained open as late as 50 months of follow-up.15
Common complications of airway stenting are mucosal
oversecretion, formation of granulation tissue, and stent mi-
gration.20 We could reliably see hyperplasia of mucosal
goblet cells, which most likely encouraged oversecretion
and formation of granulation tissue. There was no stent mi-
gration, nor were there any stent remnants or debris. Disap-
pearance of the stent could therefore theoretically be caused
by removal of remnants through coughing, swallowing, and
ingestion. The changes in radial force are important for mi-
gration prevention. High radial force holds the airway open
better, and the stent shortens more predictably; however, it
presents a certain risk of erosion. Stents with zero radial
force will not erode, but they do have a tendency toward dis-
placement. Clinical studies to compare tissue reactions to
varying radial forces are needed.
Currently, there are other methods of description for the
specific characteristics of self-expandable stents avail-
able.21 Chronic outward force describes the exertion of
the stent to expand to its nominal diameter. Radial resistive
force measures the resistance of the stent to constrictive
forces. The opening forces of the ideal stent should be
low, to avoid irritation and damage through damage of the
stented wall. On the other hand, the resistance to forces
closing the lumen should be high.22 In our study, chronic
outward forcewas holding the stent in place (fully expanded
stent outer diameter 6 mm vs inner diameter of rabbit tra-
chea of approximately 5.6 mm). This expansion force did
not cause any permanent injury to the tracheal mucosa.
Our histopathologic findings revealed that all experimen-
tal groups had significantly different TDS values from that
of the nonstented control group (Figure 1). During the first
2 weeks, we observed only mild clinical signs of respiratory
distress. It seems that signs of obstruction increased when
the reparative processes of respiratory mucosal hyperplasia
started. In compliance with clinical signs, the most pro-
nounced inflammation has been histologically observed at
the 5th week after implantation. The inflammatory reaction
and reparation caused the most marked restriction of the tra-
cheal lumen in this period. In 1 animal, we observed tra-
cheal cartilage necrosis. This was caused rather by the
increased enzymatic activity of neutrophils rather than by
the minimal mechanical compression. We were able to
demonstrate both macroscopically and microscopically
the regression of inflammatory reaction from week 5 to
week 15. Observed hyperplasia of the tracheal mucosa
has also been observed in rat models of tracheal stenting;
however, that experiment only lasted 3 weeks.23
Microorganisms and inflammatory reaction speed up the
loss of tensile strength of the polydioxanone stents.24The Journal of Thoracic and CaIn vitro, polydioxanone has moderate initial tensile
strength, and it loses approximately 30% of its initial
strength in 3 weeks of degradation and 60% of its initial
strength in 6 weeks.25 In our study, the stent disappeared be-
tween the 5th and 10th week after implantation. There were
no signs of any residual polydioxanone fibers in the epithe-
lium or lamina propria after 15 weeks. The amount of gran-
ulation tissue had already decreased by that point, with only
minimal scar tissue and residual lymphoplasmacytic infil-
tration. One animal from the control group also had mini-
mal inflammatory infiltration in the tracheal mucosa, most
likely caused, however, by a reaction to environmental
antigens.
Limitations of the Study
The size of the stents was chosen arbitrarily. Our oversiz-
ing of 15%may have created a bias, because the stents may
have exerted different forces against the variously sized tra-
cheal walls of the individual animals. It would probably be
better to perform preoperative imaging and exact measure-
ments of the individual tracheas to help choose stents of ex-
actly the desired sizes.
Our result of normal airway stenting can neither confirm
nor exclude an assumption that an injured or strictured air-
way would respond to a biodegradable stent with a greater
degree of inflammation and a higher TDS. Only stenting of
an experimentally created airway stricture could answer
that question.
The histologic TDS evaluation was not blinded and was
performed by a single observer (L.N.). This could create
a potential bias, although any such bias should have been
mitigated by the number of samples.
There were no in vitro tests performed on 6 3 30-mm
polydioxanone stents. We instead adopted previous results
from the manufacturer’s testing of esophageal polydioxa-
none stents measuring 23 mm 3 18 mm 3 23 mm 3
60 mm (dog bone) and larger bronchial polydioxanone
stents measuring 12 mm 3 40 mm.
CONCLUSIONS
This rabbit airway model has shown the excellent bio-
compatibility of a new biodegradable polydioxanone stent.
Clinical results suggest that although these stents cause
temporary respiratory distress, they are well tolerated, sup-
port the tracheal wall, and completely disappear 10 weeks
after implantation. Five weeks later (15 weeks after implan-
tation), only mild lymphoplasmacytic inflammation and
minimal residual scar tissue remained. We therefore can
suggest polydioxanone stenting for future clinical studies
in which complete stent degradation after temporary airway
treatment is desirable.
We are indebted to Dr Ladislav Kalas for skilled assistance with
picture processing.rdiovascular Surgery c Volume 143, Number 2 443
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